vs
Side-by-side financial comparison of Blue Foundry Bancorp (BLFY) and Verastem, Inc. (VSTM). Click either name above to swap in a different company.
Blue Foundry Bancorp is the larger business by last-quarter revenue ($13.3M vs $11.2M, roughly 1.2× Verastem, Inc.). Blue Foundry Bancorp runs the higher net margin — -27.4% vs -876.3%, a 849.0% gap on every dollar of revenue.
Blue Foundry Bancorp is a regional bank holding company based in New Jersey, United States. It offers a comprehensive range of personal and commercial banking products, including deposit accounts, consumer loans, mortgage services, and business financing solutions, serving local individual consumers and small to medium-sized enterprises.
Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.
BLFY vs VSTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.3M | $11.2M |
| Net Profit | $-3.5M | $-98.5M |
| Gross Margin | — | — |
| Operating Margin | — | -362.2% |
| Net Margin | -27.4% | -876.3% |
| Revenue YoY | 34.2% | — |
| Net Profit YoY | -30.6% | -311.1% |
| EPS (diluted) | $-0.18 | $-1.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.3M | — | ||
| Q3 25 | $12.6M | $11.2M | ||
| Q2 25 | $12.0M | $2.1M | ||
| Q1 25 | $11.1M | — | ||
| Q4 24 | $9.9M | — | ||
| Q3 24 | $9.5M | $0 | ||
| Q2 24 | $10.1M | $10.0M | ||
| Q1 24 | $9.9M | — |
| Q4 25 | $-3.5M | — | ||
| Q3 25 | $-1.9M | $-98.5M | ||
| Q2 25 | $-2.0M | $-25.9M | ||
| Q1 25 | $-2.7M | — | ||
| Q4 24 | $-2.7M | — | ||
| Q3 24 | $-4.0M | $-24.0M | ||
| Q2 24 | $-2.3M | $-8.3M | ||
| Q1 24 | $-2.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -362.2% | ||
| Q2 25 | — | -2047.9% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -182.8% | ||
| Q1 24 | — | — |
| Q4 25 | -27.4% | — | ||
| Q3 25 | -14.8% | -876.3% | ||
| Q2 25 | -16.2% | -1213.6% | ||
| Q1 25 | -24.2% | — | ||
| Q4 24 | -28.4% | — | ||
| Q3 24 | -42.7% | — | ||
| Q2 24 | -23.2% | -82.6% | ||
| Q1 24 | -28.8% | — |
| Q4 25 | $-0.18 | — | ||
| Q3 25 | $-0.10 | $-1.35 | ||
| Q2 25 | $-0.10 | $-0.62 | ||
| Q1 25 | $-0.13 | — | ||
| Q4 24 | $-0.12 | — | ||
| Q3 24 | $-0.19 | $-0.60 | ||
| Q2 24 | $-0.11 | $-0.31 | ||
| Q1 24 | $-0.13 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $53.1M | $137.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $312.7M | $-15.5M |
| Total Assets | $2.2B | $176.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.1M | — | ||
| Q3 25 | $44.1M | $137.7M | ||
| Q2 25 | $41.9M | $164.3M | ||
| Q1 25 | $46.2M | — | ||
| Q4 24 | $42.5M | — | ||
| Q3 24 | $76.1M | $113.2M | ||
| Q2 24 | $60.3M | $83.4M | ||
| Q1 24 | $53.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $40.5M | ||
| Q2 24 | — | $40.3M | ||
| Q1 24 | — | — |
| Q4 25 | $312.7M | — | ||
| Q3 25 | $314.4M | $-15.5M | ||
| Q2 25 | $321.3M | $36.1M | ||
| Q1 25 | $326.7M | — | ||
| Q4 24 | $332.2M | — | ||
| Q3 24 | $339.3M | $11.1M | ||
| Q2 24 | $345.6M | $18.9M | ||
| Q1 24 | $350.2M | — |
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.2B | $176.9M | ||
| Q2 25 | $2.1B | $196.3M | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.1B | $126.4M | ||
| Q2 24 | $2.0B | $105.7M | ||
| Q1 24 | $2.0B | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.66× | ||
| Q2 24 | — | 2.14× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.0M | $-36.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-8.0M | — | ||
| Q3 25 | $-255.0K | $-36.2M | ||
| Q2 25 | $2.0M | $-32.7M | ||
| Q1 25 | $-3.8M | — | ||
| Q4 24 | $5.1M | — | ||
| Q3 24 | $-3.7M | $-23.8M | ||
| Q2 24 | $14.1M | $-27.6M | ||
| Q1 24 | $-4.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $4.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-27.6M | ||
| Q1 24 | $-4.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 49.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -275.8% | ||
| Q1 24 | -49.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.4% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | 0.1% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
